CIPA 2021: Covid-19 IP waiver could lead to ‘legal uncertainty’

Waiver could create confusion for research, pharma and biotech companies and the patented technology that has led to the development of vaccines

Want to view the entire article? Click here: CIPA 2021: Covid-19 IP waiver could lead to ‘legal uncertainty’

The article was originally posted on IPMagazine.
Each article is copyrighted to its original authors. We do not own any rights to the news or the images used. Whilst every care is taken to ensure that the news posts published are accurate, we cannot guarantee the authenticity of the news article on every occasion. There’s no copyright infringement intended. The news is for informational purposes only and does not provide legal advice.